Literature DB >> 2846345

Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers.

M Linden1, E Wieslander, A Eklund, K Larsson, R Brattsand.   

Abstract

Bronchoalveolar lavage (BAL) was performed in fourteen healthy non-smokers and eleven healthy smokers. In smokers BAL was performed before and after eight weeks' treatment with N-acetylcysteine (NAC; 200 mg t.i.d.). Cell number, composition and viability were determined in the BAL fluid. Alveolar macrophages (AMs) were cultured before examination of their phagocytic capacity and their ability to produce leukotriene B4 (LTB4). BAL fluid from smokers contained more cells than that from non-smokers (p less than 0.001). This was mainly attributable to increases in both proportion and absolute number of AMs (p less than 0.001) and to an increase in absolute number of neutrophils (p less than 0.05). However, there was a decrease in proportion of lymphocytes in BAL fluid from smokers (p less than 0.001). Phagocytic capacity of adherent cells and capacity of AMs to generate LTB4 after stimulation with opsonized zymosan (OZy) were decreased in smokers (p less than 0.05 and p less than 0.01 respectively). NAC treatment of smokers did not affect cell number but resulted in an increased proportion of lymphocytes in BAL fluid (p less than 0.05). The phagocytic capacity of AMs was not significantly altered but was improved in five of eleven smokers after NAC treatment. NAC also enhanced the decreased LTB4 secretion by smokers' AMs (p less than 0.05). We conclude that smoking leads to reduced phagocytic capacity and LTB4 secretion of AMs and that oral NAC treatment may improve the function of AMs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846345

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Proc Am Thorac Soc       Date:  2005

2.  N-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid.

Authors:  W A De Backer; B Amsel; P G Jorens; L Bossaert; P S Hiemstra; P van Noort; F J van Overveld
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

3.  Effect of N-acetyl cysteine on thiol levels.

Authors:  P N Dekhuijzen; C L Van Herwaarden
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

4.  Effects of an inhaled corticosteroid, budesonide, on alveolar macrophage function in smokers.

Authors:  H Bergstrand; A Björnson; E Blaschke; R Brattsand; A Eklund; K Larsson; M Linden
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

5.  Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.

Authors:  Rokhsara Rafii; Timothy E Albertson; Samuel Louie; Andrew L Chan
Journal:  Pulm Med       Date:  2011-04-20

Review 6.  Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.

Authors:  Hoi Nam Tse; Cee Zhung Steven Tseng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-08-06

Review 7.  N-acetylcysteine in COPD: why, how, and when?

Authors:  Claudio M Sanguinetti
Journal:  Multidiscip Respir Med       Date:  2016-02-03

Review 8.  The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Lung Architecture Remodeling.

Authors:  Anantha Harijith; Viswanathan Natarajan; Panfeng Fu
Journal:  Antioxidants (Basel)       Date:  2017-12-19

Review 9.  The role for N-acetylcysteine in the management of COPD.

Authors:  P N R Dekhuijzen; W J C van Beurden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.